Hart and Louise Lyon Immunology Laboratory, Section of Clinical Immunology/Allergy, Division of Pulmonary, Critical Care and Clinical Immunology/Allergy, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1690, USA.
Allergy. 2012 May;67(5):622-9. doi: 10.1111/j.1398-9995.2012.02798.x. Epub 2012 Feb 17.
Treatment options for food allergy remain limited. Development of novel approaches for the prevention and/or treatment of severe peanut allergy and other food allergies is urgently needed. The objective of this study was to test whether skin application of food allergen can be used as a prophylactic and/or therapeutic intervention for food allergy.
Balb/C mice were given 5 weekly cutaneous application of complete peanut extract (CPE) or ovalbumin (OVA) ranging from 10 to 1000 μg on the shaved back skin, followed by 5 weekly treatments with oral CPE or OVA plus cholera toxin to induce allergic reactivity to the food. At various time points, the immunologic responses and allergic clinical manifestations to allergens were examined.
Skin application of a 10-1000 μg dose of CPE or OVA to structurally intact skin did not lead to allergic sensitization to peanut or OVA. Rather, cutaneous allergen application blocked, in a dose-dependent fashion, the subsequent induction of the oral sensitization including inhibiting oral sensitization-induced CPE-specific IgE, IgG1, and IgG2a production, suppressing the peanut anaphylaxis, and modulating the oral sensitization-promoted cytokine production. The cutaneous OVA application also resulted in similar results as seen with CPE application.
Cutaneous application of intact skin with peanut or OVA can block the development of orally induced corresponding food allergies, suggesting that allergic tolerance to peanuts and OVA might be achieved via allergen cutaneous application.
食物过敏的治疗选择仍然有限。迫切需要开发新的方法来预防和/或治疗严重的花生过敏和其他食物过敏。本研究的目的是测试食物过敏原的皮肤应用是否可用于预防和/或治疗食物过敏。
Balb/C 小鼠每周在剃光的背部皮肤上接受 5 次完整花生提取物 (CPE) 或卵清蛋白 (OVA) 的皮肤应用,剂量范围为 10 至 1000 μg,随后每周用 CPE 或 OVA 加霍乱毒素进行 5 次口服治疗,以诱导对食物的过敏反应。在不同时间点,检查了针对过敏原的免疫反应和过敏临床症状。
将 10-1000 μg 剂量的 CPE 或 OVA 应用于结构完整的皮肤不会导致对花生或 OVA 的过敏致敏。相反,皮肤过敏原应用以剂量依赖性方式阻断了随后的口服致敏诱导,包括抑制口服致敏诱导的 CPE 特异性 IgE、IgG1 和 IgG2a 产生,抑制花生过敏反应,并调节口服致敏促进的细胞因子产生。皮肤 OVA 应用也产生了与 CPE 应用相似的结果。
完整皮肤用花生或 OVA 的皮肤应用可以阻断口服诱导的相应食物过敏的发展,这表明通过过敏原皮肤应用可能实现对花生和 OVA 的过敏耐受。